Appili Therapeutics Inc Class A (TSE:APLI) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Appili Therapeutics has received the final court approval for its acquisition by Aditxt, Inc., marking a significant milestone in the transaction process. This move will eventually lead to Appili’s delisting from the Toronto Stock Exchange. The transaction is expected to close by the end of 2024, subject to remaining conditions.
For further insights into TSE:APLI stock, check out TipRanks’ Stock Analysis page.
